MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Fate Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.14 4.59

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.09

Max

1.16

Pagrindiniai rodikliai

By Trading Economics

Pajamos

15M

-38M

Pardavimai

-231K

1.6M

Pelno marža

-2,309.454

Darbuotojai

181

EBITDA

4.3M

-38M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+348.62% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

5.8M

128M

Ankstesnė atidarymo kaina

-3.45

Ankstesnė uždarymo kaina

1.14

Naujienos nuotaikos

By Acuity

58%

42%

322 / 376 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Fate Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-09 15:46; UTC

Pagrindinės rinkos jėgos

BitMine Shares Fall After Closing of $250 Million Private Placement

2025-07-09 23:44; UTC

Rinkos pokalbiai

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

2025-07-09 23:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-09 23:42; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

2025-07-09 22:59; UTC

Rinkos pokalbiai

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

2025-07-09 22:59; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-09 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-07-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-09 20:26; UTC

Uždarbis

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

2025-07-09 19:18; UTC

Rinkos pokalbiai

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

2025-07-09 19:03; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

2025-07-09 18:31; UTC

Rinkos pokalbiai

Some Fed Officials Supported Considering July Cut -- Market Talk

2025-07-09 17:07; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

2025-07-09 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk -2-

2025-07-09 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-07-09 16:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-07-09 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-09 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-09 16:14; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-09 16:14; UTC

Rinkos pokalbiai

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

2025-07-09 16:14; UTC

Įsigijimai, susijungimai, perėmimai

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

2025-07-09 16:12; UTC

Rinkos pokalbiai

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

2025-07-09 16:08; UTC

Rinkos pokalbiai

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

2025-07-09 15:31; UTC

Pagrindinės rinkos jėgos

BitMine Shares Fall After Closing of $250M Private Placement

2025-07-09 15:31; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

2025-07-09 15:27; UTC

Rinkos pokalbiai

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

2025-07-09 14:36; UTC

Įsigijimai, susijungimai, perėmimai

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

2025-07-09 14:31; UTC

Įsigijimai, susijungimai, perėmimai

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

2025-07-09 14:26; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-07-09 14:26; UTC

Rinkos pokalbiai

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Akcijų palyginimas

Kainos pokytis

Fate Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

348.62% į viršų

12 mėnesių prognozė

Vidutinis 4.89 USD  348.62%

Aukščiausias 12 USD

Žemiausias 2 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fate Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

10 ratings

2

Pirkti

8

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.9101 / 1.14Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

322 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.